The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study
Publication
, Conference
Gordon, SC; Muir, AJ; Lim, JK; Pearlman, B; Argo, CK; Neff, GW; Ramani, A; Maliakkal, B; Rodriguez-Torres, M; Stewart, T; Fried, MW; Reddy, KR
Published in: HEPATOLOGY
October 1, 2013
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2013
Volume
58
Start / End Page
1104A / 1105A
Location
Washington, DC
Publisher
WILEY-BLACKWELL
Conference Name
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Gordon, S. C., Muir, A. J., Lim, J. K., Pearlman, B., Argo, C. K., Neff, G. W., … Reddy, K. R. (2013). The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study. In HEPATOLOGY (Vol. 58, pp. 1104A-1105A). Washington, DC: WILEY-BLACKWELL.
Gordon, Stuart C., Andrew J. Muir, Joseph K. Lim, Brian Pearlman, Curtis K. Argo, Guy W. Neff, Ananthakrishnan Ramani, et al. “The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study.” In HEPATOLOGY, 58:1104A-1105A. WILEY-BLACKWELL, 2013.
Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Neff GW, et al. The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study. In: HEPATOLOGY. WILEY-BLACKWELL; 2013. p. 1104A-1105A.
Gordon, Stuart C., et al. “The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study.” HEPATOLOGY, vol. 58, WILEY-BLACKWELL, 2013, pp. 1104A-1105A.
Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Neff GW, Ramani A, Maliakkal B, Rodriguez-Torres M, Stewart T, Fried MW, Reddy KR. The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study. HEPATOLOGY. WILEY-BLACKWELL; 2013. p. 1104A-1105A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2013
Volume
58
Start / End Page
1104A / 1105A
Location
Washington, DC
Publisher
WILEY-BLACKWELL
Conference Name
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics